Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2026-02-26

FDA Approved: ENSACOVE — Supplemental Application (Xcovery Holdings, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ENSACOVE (ensartinib) to update the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ENSACOVE (ensartinib)

Snippet

SUPPL AP for ENSACOVE (ENSARTINIB)